The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

Opens in a new tab or window The FDA approved marstacimab ... It is the first anti-TFPI approved in the U.S. for the treatment of hemophilia A or B. "Today's approval of Hympavzi provides patients ...

Opens in a new tab or window The FDA on Thursday approved xanomeline and trospium ... (P<0.0001 for both): EMERGENT-2: -21.2 vs -11.6, respectively EMERGENT-3: 20.6 vs -12.2 And some key secondary ...

A nasal spray version of the annual flu vaccine can now be taken at home, the U.S. Food and Drug Administration (FDA) says. In a statement published Sept. 20, the FDA announced that it had ...

Eczema, also known as atopic dermatitis, is an inflammatory skin condition that can cause itching, rashes and dry patches. The FDA's approval was ... in Black patients 6:38 PM UTC Oil prices ...

A home version of the nasal flu vaccine FluMist was just approved by the U.S. Food and Drug Administration ... subtypes A and B. Adults 50 and older and children between 6 months and 2 years ...

A new gene therapy approved earlier this year can serve as a sustainable single-dose treatment for people with hemophilia B ... finds 6% of U.S. adults have ADHD amid ongoing drug shortages ...

The drug is now pending a final decision from the European Commission. The EMA granted Hympavzi orphan status for treating hemophilia B in December ... or factor IX over a 6-month observational ...